Table 3.
Subgroup analyses of vitamin D with calcium vs placebo on risk of hip and any fracture
| Hip fracture | Any fracture | |
|---|---|---|
| By age, y | Yao et al, 2019 (30): < 80: 0.92 (0.77-1.10) ≥ 80: 0.69 (0.53-0.90) P (interaction): NA P (heterogeneity): .07 |
Yao et al, 2019 (30): < 80: 0.96 (0.90-1.02) ≥ 80: 0.76 (0.62-0.92) P (interaction): NA P (heterogeneity): .02 |
| By sex | Zhao et al, 2017 (31): Women only: 1.07 (0.79-1.46) Both: 1.12 (0.75-1.68) P (interaction): .86 |
Zhao et al, 2017 (31): Women only: 0.88 (0.71-1.08) Both: 0.83 (0.48-1.42) P (interaction): .84 |
| By history of osteoporotic fracture | Zhao et al, 2017 (31): Yes: 1.12 (0.75-1.68) Othera: 1.07 (0.79-1.46) P (interaction): .86 |
Zhao et al, 2017 (31): Yes: 0.92 (0.76-1.11) Othera: 0.88 (0.71-1.09) P (interaction): .78 |
| Avenell et al, 2014 (15): Yes: 1.02 (0.71, 1.47) No: 0.82 (0.71, 0.94) P (interaction): .26 |
Avenell et al, 2014 (15): Yes: 0.93 (0.79-1.10) No: 0.95 (0.90-1.00) P (interaction): .84 |
|
| By baseline serum 25(OH)D concentration, nmol/L | Zhao et al, 2017 (31): ≥50: 0.36 (0.01-8.78) < 50: 1.14 (0.88-1.48) P (interaction): .48 |
Zhao et al, 2017 (31): ≥50: 1.87 (0.32-11.02) < 50: 0.90 (0.76-1.05) P (interaction): .42 |
| Bolland et al, 2014 (19): ≥ 50: 0.36 (0.02-8.79) < 50: 0.84 (0.74-0.97) P (interaction): .82 |
Bolland et al, 2014 (19): ≥ 50: 1.50 (1.02-2.19) < 50: 0.75 (0.43-1.31) P (interaction): .24 |
|
| By D dose | Zhao et al (with Ca), 2017 (31): ≥ 1 g and ≥ 800 IU: 1.06 (0.74-1.51) Another dose: 1.12 (0.80-1.57) P (interaction): .83 |
Zhao et al (with Ca), 2017 (31): ≥ 1g and ≥ 800 IU: 0.90 (0.78-1.04) Another dose: 1.15 (0.28-4.74) P (interaction): .74 |
| DIPART, 2010 (23): 10 μg: 0.74 (0.60-0.91) 20 μg: 1.30 (0.88-1.91) P (interaction): NA |
DIPART, 2010 (23): 10 μg: 0.91 (0.85-0.99) 20 μg: 0.95 (0.80, 1.14) P (interaction): NA |
|
| Other subgroup analyses | Yao et al, 2019 (30): region, open-label, Ca dose (1000 mg-1200 mg), treatment difference in 25(OH)D (< 50 nmol/L-≥ 50 nmol/L) Bolland et al, 2014 (19): achieved 25(OH)D (nmol/L), duration of trial Zhao et al, 2017 (31): Ca dose (< 1 g-≥ 1 g), dietary Ca intake (< 900 mg-≥ 900 mg), dose frequency Weaver et al, 2016 (29): use of personal supplements, adherence to assigned study pills in WHI |
Units listed as reported; to convert from nmol/L to ng/mL, divide by 2.496.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; C, community-dwelling individuals; Ca, calcium; D, vitamin D; I, institutionalized; NA, not available; WHI, Women’s Health Initiative.
a Other includes no fracture, partial fracture, or missing fracture data.